Proteomics discovery of MTDH and SND1 interaction vulnerabilities in ovarian cancer
(2025) In Scientific Reports 15(1).- Abstract
High-grade serous ovarian cancer (HGSOC) is the most prevalent and aggressive subtype of ovarian cancer. The combination of late-stage diagnosis and the tendency to exhibit resistance to existing treatments highlights a critical gap in effective therapeutic options. There is thus a need for novel strategies for targeting HGSOC, particularly in its advanced stages. To address this gap, we developed a comprehensive atlas profiling both the proteome and phosphoproteome levels across a panel of nine ovarian cancer cell lines from different subtypes. Subsequent differential expression analysis between the KURAMOCHI and the other cell lines, followed by phosphosite analyses, proposed the MTDH protein as a potential target. Further functional... (More)
High-grade serous ovarian cancer (HGSOC) is the most prevalent and aggressive subtype of ovarian cancer. The combination of late-stage diagnosis and the tendency to exhibit resistance to existing treatments highlights a critical gap in effective therapeutic options. There is thus a need for novel strategies for targeting HGSOC, particularly in its advanced stages. To address this gap, we developed a comprehensive atlas profiling both the proteome and phosphoproteome levels across a panel of nine ovarian cancer cell lines from different subtypes. Subsequent differential expression analysis between the KURAMOCHI and the other cell lines, followed by phosphosite analyses, proposed the MTDH protein as a potential target. Further functional analyses of MTDH and the interacting protein SND1 with RNA silencing, as well as targeting their interaction, revealed that disrupting this interaction leads to the dysregulation of several pathways associated with cancer progression and invasion. In particular, interference with the MTDH-SND1 complex was associated with enrichment of ferroptosis-related pathways. Moreover, combining C26A6 treatment with ferroptosis inducers produced enhanced inhibitory effects in ovarian cancer cells, suggesting a possible strategy for targeting cancer cell vulnerabilities in HGSOC, which warrants further investigation beyond in vitro models.
(Less)
- author
- Esmaeili, Parisa
LU
; Nasimian, Ahmad
LU
; Werner, Lucas
LU
; Junior, Sergio Mosquim
LU
; Jakobsson, Magnus E
LU
; Gerdtsson, Anna Sandström
LU
; Kazi, Julhash U
LU
and Levander, Fredrik
LU
- organization
-
- LTH Profile Area: Engineering Health
- Division of Translational Cancer Research
- Department of Immunotechnology
- Breast cancer treatment
- LUCC: Lund University Cancer Centre
- eSSENCE: The e-Science Collaboration
- StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
- LTH Profile Area: Food and Bio
- publishing date
- 2025-11-24
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Humans, Female, Ovarian Neoplasms/metabolism, RNA-Binding Proteins, Membrane Proteins/metabolism, Proteomics/methods, Cell Line, Tumor, Cell Adhesion Molecules/metabolism, Gene Expression Regulation, Neoplastic, Nuclear Proteins/metabolism, Proteome, Endonucleases
- in
- Scientific Reports
- volume
- 15
- issue
- 1
- article number
- 41818
- publisher
- Nature Publishing Group
- external identifiers
-
- scopus:105022795058
- pmid:41286067
- ISSN
- 2045-2322
- DOI
- 10.1038/s41598-025-26913-1
- language
- English
- LU publication?
- yes
- additional info
- © 2025. The Author(s).
- id
- c2e4a69b-709d-48c4-9937-bc814920638a
- date added to LUP
- 2025-12-26 22:01:08
- date last changed
- 2026-01-10 05:29:00
@article{c2e4a69b-709d-48c4-9937-bc814920638a,
abstract = {{<p>High-grade serous ovarian cancer (HGSOC) is the most prevalent and aggressive subtype of ovarian cancer. The combination of late-stage diagnosis and the tendency to exhibit resistance to existing treatments highlights a critical gap in effective therapeutic options. There is thus a need for novel strategies for targeting HGSOC, particularly in its advanced stages. To address this gap, we developed a comprehensive atlas profiling both the proteome and phosphoproteome levels across a panel of nine ovarian cancer cell lines from different subtypes. Subsequent differential expression analysis between the KURAMOCHI and the other cell lines, followed by phosphosite analyses, proposed the MTDH protein as a potential target. Further functional analyses of MTDH and the interacting protein SND1 with RNA silencing, as well as targeting their interaction, revealed that disrupting this interaction leads to the dysregulation of several pathways associated with cancer progression and invasion. In particular, interference with the MTDH-SND1 complex was associated with enrichment of ferroptosis-related pathways. Moreover, combining C26A6 treatment with ferroptosis inducers produced enhanced inhibitory effects in ovarian cancer cells, suggesting a possible strategy for targeting cancer cell vulnerabilities in HGSOC, which warrants further investigation beyond in vitro models.</p>}},
author = {{Esmaeili, Parisa and Nasimian, Ahmad and Werner, Lucas and Junior, Sergio Mosquim and Jakobsson, Magnus E and Gerdtsson, Anna Sandström and Kazi, Julhash U and Levander, Fredrik}},
issn = {{2045-2322}},
keywords = {{Humans; Female; Ovarian Neoplasms/metabolism; RNA-Binding Proteins; Membrane Proteins/metabolism; Proteomics/methods; Cell Line, Tumor; Cell Adhesion Molecules/metabolism; Gene Expression Regulation, Neoplastic; Nuclear Proteins/metabolism; Proteome; Endonucleases}},
language = {{eng}},
month = {{11}},
number = {{1}},
publisher = {{Nature Publishing Group}},
series = {{Scientific Reports}},
title = {{Proteomics discovery of MTDH and SND1 interaction vulnerabilities in ovarian cancer}},
url = {{http://dx.doi.org/10.1038/s41598-025-26913-1}},
doi = {{10.1038/s41598-025-26913-1}},
volume = {{15}},
year = {{2025}},
}